TUDCA: A New Way of Addressing Insulin Resistance

Summary

The video examines whether tauroursodeoxycholic acid (TUDCA) could help address insulin resistance. The presenter describes the idea as promising but emphasizes that human evidence is limited and needs stronger confirmation.

Main Ideas

• Insulin resistance occurs when cells respond poorly to insulin, making it harder for glucose to move from the blood into cells. Improving insulin sensitivity may help counter this.
• The liver makes bile acids. Gut bacteria can convert some bile acids into ursodeoxycholic acid (UDCA), which returns to the liver and can be converted into TUDCA.
• TUDCA is proposed to ease stress on the endoplasmic reticulum (ER), a cell structure involved in folding and maturing proteins. ER stress and misfolded proteins may promote inflammatory signaling and interfere with insulin signaling.

Evidence Discussed

• In a study of people with insulin resistance, defined as a HOMA-IR score above 3, the group taking TUDCA showed about a 30% improvement in insulin sensitivity from baseline. The placebo group did not show the same improvement.
• The reported benefit appeared in the liver and muscle, but not in adipose (fat) tissue, suggesting that effects may vary by tissue.
• At the cellular level, TUDCA was associated with greater activation of insulin-signaling proteins IRS1 and AKT, which are involved in the pathway that helps cells take up glucose.
• The presenter also discusses a small study of UDCA—not TUDCA—in which HbA1c and HOMA-IR improved. This was a pilot study without a control group, so its results are preliminary.

Practical Considerations and Limitations

• TUDCA and UDCA are related but not identical, and the evidence reviewed includes studies of both.
• Human research is sparse, with few studies in each area, and some findings are preliminary. The presenter cautions against treating TUDCA as an established solution for insulin resistance.
• Possible gastrointestinal side effects include diarrhea, indigestion, and discomfort.
• Study doses ranged from 250 to 2,000 mg per day. The presenter says doses of 1,000 mg per day or more were generally the most effective in the studies discussed. This describes study dosing and is not individualized medical advice.

Speakers and Sources

• Speaker: A single narrator/presenter from the Physionic channel.
• Sources discussed: Human studies of TUDCA and UDCA, including a placebo comparison and a small UDCA pilot study. The subtitles do not provide study authors or full citations.